# Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

Source: https://onco.cc/trials/nct05532696/  
OnCo record `nct05532696` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ABT-101 in non-small-cell lung cancer, run by Anbogen Therapeutics, Inc., now recruiting.

## Summary

Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients is a phase 1/2 interventional study registered as NCT05532696 by Anbogen Therapeutics, Inc., with 61 participants planned, started 2022-09-27 and due to reach its primary completion in 2026-11. Interventions recorded: ABT-101.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05532696
- Phase: 1/2
- Setting: A Phase Ib/II, Open-Label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ABT-101 in Patients With Advanced Solid Tumors and HER2 Exon 20 Insertions Mutated Non- Small Cell Lung Cancer
- Sponsor: Anbogen Therapeutics, Inc.
- Enrolled: 61

## Sources

- ClinicalTrials.gov NCT05532696: https://clinicaltrials.gov/study/NCT05532696

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct05532696.json